secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arbutus Biopharma Corp (ABUS)
CIK:        0001447028
Form:       8-K
Filed at:   2025-03-03T23:59:59+00:00
Accession:  0001171843-25-001188
Event type: litigation
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arbutus and Genevant file 5 international patent lawsuits against Moderna; terminate sublicense for breach
--------------------------------------------------------------------------------

- Agreement entitles Arbutus to damages specifically allocated to Moderna's mRESVIA in pending U.S. litigation; if no allocation, parties discuss in good faith.
- Arbutus terminated 2016 sublicense with ModernaTX for material breach over unpaid milestone/royalty payments; 60-day cure period.
- Five lawsuits filed in Canada, Japan, Switzerland, and two UPC actions covering 30 countries, seeking injunctions and monetary relief against Spikevax and mRESVIA.
- U.S. jury trial against Moderna in Delaware currently scheduled for September 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1447028/000117184325001188/0001171843-25-001188-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1447028/000117184325001188/f8k_030325.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-001188

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer